CARDINAL HEALTH INC
Customers
2
2 active
Suppliers
21
16 active
Largest customer
29%
Group Purchasing Organizations · FY to 2026-06-30
Named-customer revenue
$144.9B
2 customers · FY to 2026-06-30
Latest period
Jul 3, 2026
10-Q filed 2026-08-05
Customers 2
Companies CAH discloses as major customers, as a share of CAH revenue. 2 active, 0 lapsed.
| Company | % of CAH revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Group Purchasing Organizations Non-SEC Group Purchasing Organizations |
29% | $73.7B | FY 2026-06-30 | +2.0pp | Active | 10-K 2026-08-11 |
We have agreements with group purchasing organizations (“GPOs”) that act as agents to negotiate vendor contracts on behalf of their members. | ||||||
| CVS CVS HEALTH Corp |
28% | $71.2B | FY 2026-06-30 | −2.0pp | Active | 10-K 2026-08-11 |
CVS Health 28 % 30 % 24 % 22 % 26 % | ||||||
Suppliers 21
Companies that disclose CAH as a major customer, as a share of their own revenue. 16 active, 5 lapsed.
| Company | % of their revenue | Est. $ from CAH | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| GILD GILEAD SCIENCES, INC. |
29% | $8.5B | FY 2025-12-31 | ±0.0pp | Active | 10-K 2026-02-24 |
Cardinal Health, Inc. (“Cardinal Health”) 29 % 29 % 28 % | ||||||
| ADCT ADC Therapeutics SA |
23% | $4.3M | 3M 2026-06-30 | −2.0pp | Active | 10-Q 2026-08-13 |
Cardinal Health 23 % 21 % 24 % 23 % Cardinal Health 25 % 24 % Cardinal Health 22 % 24 % Cardinal Health 19 % 26 % 21 % 24 % | ||||||
| BMY BRISTOL MYERS SQUIBB CO |
22% | $10.6B | FY 2025-12-31 | ±0.0pp | Active | 10-K 2026-02-11 |
Cardinal Health, Inc. 22 % 22 % 23 % | ||||||
| ALKS Alkermes plc. |
17% | $250.9M | FY 2025-12-31 | −2.0pp | Active | 10-K 2026-02-25 |
The following represents revenue and receivables from the Company’s customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2025, 2024 and 2023: Year Ended December 31, 2025 2024 2023 Customer Receivables Revenue Receivables Revenue Receivables Revenue McKesson 33 % 31 % 36 % 25 % 14 % 14 % Cencora 26 % 20 % 17 % 15 % 16 % 12 % Cardinal Health 17 % 17 % 16 % 19 % 24 % 20 % Janssen 12 % * 14 % 17 % 23 % 31 % Biogen * * * 11 % * 11 % * Indicates the revenues or receivables for the customer did not exceed 10% of the Company’s total in each category as of or for the years ended December 31, 2025, 2024 and 2023, as noted. | ||||||
| AMPH Amphastar Pharmaceuticals, Inc. |
16% | $29.4M | 3M 2026-06-30 | −3.0pp | Active | 10-Q 2026-08-06 |
Cardinal Health 11 % 12 % 16 % 21 % 17 % 20 % Cardinal Health 14 % 12 % 19 % 20 % Cardinal Health 19 % 19 % 15 % Cardinal Health 16 % 16 % 21 % 20 % 20 % 20 % | ||||||
| ARDX ARDELYX, INC. |
14.4% | $17.4M | 3M 2026-06-30 | +1.6pp | Active | 10-Q 2026-08-06 |
Cardinal Health, Inc. 14.4 % 23.4 % 13.7 % 22.8 % Cardinal Health, Inc. 12.8 % 22.2 % Cardinal Health 21.4 % 14.5 % 19.8 % Cardinal Health 25.5 % 12.4 % 23.9 % 14.6 % | ||||||
| BHC Bausch Health Companies Inc. |
14% | $1.4B | FY 2025-12-31 | ±0.0pp | Active | 10-K 2026-02-19 |
Cardinal Health, Inc. 14% 14% 13% | ||||||
| PFE PFIZER INC |
13% | $8.1B | FY 2025-12-31 | −1.0pp | Active | 10-K 2026-02-26 |
Cardinal Health, Inc. 13 % 14 % 10 % | ||||||
| MRNA Moderna, Inc. |
11% | $213.8M | FY 2025-12-31 | Active | 10-K 2026-02-20 | |
Cardinal Health 11 % * * * * | ||||||
| AKBA Akebia Therapeutics, Inc. |
10% | $19.5M | FY 2023-12-31 | Lapsed Last seen 2023-12-31 |
10-K 2026-02-26 | |
Cardinal Health, Inc. * * 10 % | ||||||
| Assertio Holdings, Inc. Assertio Holdings, Inc. |
10% | $11.9M | FY 2025-12-31 | +2.0pp | Active | 10-K 2026-03-16 |
Cardinal Health 10 % 8 % 10 % 6 % | ||||||
| BLCO Bausch & Lomb Corp |
10% | $510.1M | FY 2025-12-31 | ±0.0pp | Active | 10-K 2026-02-18 |
Cardinal Health, Inc. 10 % 10 % | ||||||
| EXEL EXELIXIS, INC. |
10% | $62.9M | 3M 2026-07-03 | Active | 10-Q 2026-08-05 | |
Cardinal Health, Inc. 10 % * * * Cardinal Health, Inc. 11 % 12 % Cardinal Health, Inc. 12 % 10 % Cardinal Health, Inc. 13 % 10 % | ||||||
| RIGL RIGEL PHARMACEUTICALS INC |
10% | $6.9M | 3M 2025-09-30 | −3.0pp | Lapsed Last seen 2025-09-30 |
10-Q 2025-11-04 |
Cardinal Health, Inc. 10 % * * 15 % Cardinal Health, Inc. * 13% Cardinal Health, Inc. * 13 % 25 % | ||||||
| VTRS Viatris Inc |
5% | $769.4M | FY 2023-12-31 | Lapsed Last seen 2023-12-31 |
10-K 2026-02-26 | |
Cardinal Health, Inc. * * 5 % | ||||||
| AMRX Amneal Pharmaceuticals, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-27 |
For example, large wholesalers and retailer customers have formed alliances, such as Walgreens and Cencora, Inc., Rite Aid and McKesson Drug Company, and CVS Caremark and Cardinal Health. | ||||||
| EMBC Embecta Corp. |
Named | — | FY 2025-09-30 | — | Active | 10-K 2025-11-25 |
For example, for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta’s three largest distributors, together represented approximately 42% of Embecta’s worldwide gross sales. | ||||||
| MGNX MACROGENICS INC |
Named | — | FY 2024-12-31 | — | Lapsed Last seen 2024-12-31 |
10-K 2026-03-09 |
Cardinal Health, Inc. * 12 % | ||||||
| MRK Merck & Co., Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-24 |
The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025. | ||||||
| NVAX NOVAVAX INC |
Named | — | FY 2024-12-31 | — | Lapsed Last seen 2024-12-31 |
10-K 2026-02-26 |
Cardinal Health * * * * 10 % | ||||||
| SUPN SUPERNUS PHARMACEUTICALS, INC. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-02 |
Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of our total product revenue in 2025 and collectively accounted for more than 76% of our total product revenue in 2025. | ||||||
Alerts are coming
Get an email when CAH's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.